| Date Filed | Type | Description |
| 08/21/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 08/16/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/14/2023 |
SC 13D/A
| ELI LILLY & Co reports a 100% stake in Sigilon Therapeutics, Inc. |
| 08/11/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/11/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/11/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/11/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/11/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 08/11/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 08/11/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 08/10/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 08/10/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 08/01/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 07/18/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 07/18/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 07/13/2023 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 07/13/2023 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 07/07/2023 |
SC 13D
| ELI LILLY & Co reports a 40.3% stake in Sigilon Therapeutics, Inc. |
| 06/29/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"AGREEMENT AND PLAN OF MERGER",
"FORM OF CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●], 2023 , is entered into by and among Eli Lilly and Company, an Indiana corporation , Shenandoah Acquisition Corporation, a Delaware corporation and wholly owned Subsidiary of Parent , and [●], a [●], as Rights Agent . Capitalized terms used but not defined herein shall have the meaning assigned to such terms in the Merger Agreement . RECITALS WHEREAS, Parent, Purchaser and [SHENANDOAH], a Delaware corporation , have entered into an Agreement and Plan of Merger, dated as of June 28, 2023 , pursuant to which Purchaser has made a tender offer to acquire all of the issued and outstanding shares of common stock, par value $0.001 per share, of the Company and following the acceptan...",
"Lilly to Acquire Sigilon Therapeutics" |
|
| 06/29/2023 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/06/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/23/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/14/2023 |
8-K
| Quarterly results |
| 02/28/2023 |
8-K
| Other Events Interactive Data |
| 02/13/2023 |
8-K
| Quarterly results |
| 12/21/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
|